Back
Ultragenyx Pharmaceutical Inc (RARE)
BiotechnologyRARE · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$33.82
−2.28%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-5.83
ROE
Gross margin
-28.1%
Debt/Equity
Revenue growth
-2.2%
P/B ratio
Beta
Forward P/E
Ultragenyx Pharmaceutical Inc — company intelligence
Earnings surprises
Q1 2026$-1.84 vs $-1.54 est-19.5%
Q4 2025$-1.29 vs $-1.11 est-15.8%
Q3 2025$-1.81 vs $-1.26 est-43.7%
Q2 2025$-1.17 vs $-1.32 est+11.7%
Analyst consensus · 25 analysts
22 Buy3 Hold0 Sell
Updated Jul 10, 2026
Insider activity · 90 days
30 buys6 sellsnet +923,437 shares
Parschauer Karah HerdmanSell 1,899 · Jun 15, 2026
Sanders Corazon (Corsee) D.Sell 2,000 · Jun 15, 2026
Horn HowardSell 4,653 · Jun 1, 2026
Recent SEC filings
4 — Insider transaction reportJun 15, 2026
4 — Insider transaction reportJun 15, 2026
4 — Insider transaction reportJun 1, 2026
Latest news
RBC Capital Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $40 — Benzinga · 3d ago
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Ultragenyx Pharmaceutical Inc
Weekly undervalued picks (like RARE)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.